» Articles » PMID: 29202942

Microbiome at the Frontier of Personalized Medicine

Overview
Journal Mayo Clin Proc
Specialty General Medicine
Date 2017 Dec 6
PMID 29202942
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

The genomic revolution promises to transform our approach to treat patients by individualizing treatments, reducing adverse events, and decreasing health care costs. The early advances using this have been realized primarily by optimizing preventive and therapeutic approaches in cancer using human genome sequencing. The ability to characterize the microbiome, which includes all the microbes that reside within and upon us and all their genetic elements, using next-generation sequencing allows us to now incorporate this important contributor to human disease into developing new preventive and therapeutic strategies. In this review we highlight the importance of the microbiome in all aspects of human disease, including pathogenesis, phenotype, prognosis, and response to treatment, as well as their role as diagnostic and therapeutic biomarkers. We provide a role for next-generation sequencing in both precise microbial identification of infectious diseases and characterization of microbial communities and their function. Taken together, the microbiome is emerging as an integral part of precision medicine approach as it not only contributes to interindividual variability in all aspects of a disease but also represents a potentially modifiable factor that is amenable to targeting by therapeutics.

Citing Articles

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.

Mafe A, Busselberg D Biomedicines. 2025; 13(2).

PMID: 40002835 PMC: 11852609. DOI: 10.3390/biomedicines13020422.


Gut Microbiota-microRNA Interactions and Obesity Pathophysiology: A Systematic Review of Integrated Studies.

Azari H, George M, Albracht-Schulte K Int J Mol Sci. 2024; 25(23).

PMID: 39684547 PMC: 11640985. DOI: 10.3390/ijms252312836.


Probiotics in the Prophylaxis of Premature Rupture of Membranes and Cervical Incompetence.

Vaduva C, Petrescu A, Dira L, Ruican D, Pana R Nutrients. 2024; 16(23).

PMID: 39683623 PMC: 11644756. DOI: 10.3390/nu16234230.


Cervicovaginal and gastrointestinal microbiomes in gynecological cancers and their roles in therapeutic intervention.

Alhamlan F, Albadawi I, Al-Qahtani A, Awartani K, Obeid D, Tulbah A Front Microbiol. 2024; 15:1489942.

PMID: 39664050 PMC: 11631898. DOI: 10.3389/fmicb.2024.1489942.


Unraveling the Gut Microbiota: Implications for Precision Nutrition and Personalized Medicine.

Abeltino A, Hatem D, Serantoni C, Riente A, Giulio M, De Spirito M Nutrients. 2024; 16(22).

PMID: 39599593 PMC: 11597134. DOI: 10.3390/nu16223806.


References
1.
Wu G, Chen J, Hoffmann C, Bittinger K, Chen Y, Keilbaugh S . Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011; 334(6052):105-8. PMC: 3368382. DOI: 10.1126/science.1208344. View

2.
Bikard D, Euler C, Jiang W, Nussenzweig P, Goldberg G, Duportet X . Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014; 32(11):1146-50. PMC: 4317352. DOI: 10.1038/nbt.3043. View

3.
Schwartz D, Cantor C . Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. Cell. 1984; 37(1):67-75. DOI: 10.1016/0092-8674(84)90301-5. View

4.
Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

5.
Salipante S, SenGupta D, Cummings L, Land T, Hoogestraat D, Cookson B . Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. J Clin Microbiol. 2015; 53(4):1072-9. PMC: 4365209. DOI: 10.1128/JCM.03385-14. View